The Claim
Among French adults with early-treated phenylketonuria, the median bone mineral density Z-score at both femoral and vertebral sites is -0.6, and 11.4% of this population meet criteria for clinically significant low bone density (Z-score ≤ -2).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In French adults who were treated early for phenylketonuria, the average bone density is below the normal range for their age, and about 1 in 9 have bone density low enough to be considered clinically significant.
See the scientific wording
Among French adults with early-treated phenylketonuria, the median bone mineral density Z-score at both femoral and vertebral sites is -0.6, indicating suboptimal bone health in the overall population, with 11.4% meeting criteria for clinically significant low bone density (Z-score ≤ -2).
People with phenylketonuria must limit protein intake to avoid toxic buildup of phenylalanine, which means they get less of the amino acids needed to build and strengthen bones. This leads to thinner, weaker bones over time.
What the research says
1 studyStudy: Bone mineral density in French adults with early-treated phenylketonuria.
This study found that adults with PKU, even when treated from birth, tend to have slightly weaker bones than average, and about 1 in 9 have bones weak enough to be a health concern — which is exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.